Navigation Links
Blood Pressure Drug Does Not Help Those With Atrial Fibrillation
Date:3/9/2011

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, March 9 (HealthDay News) -- The blood pressure-lowering drug Avapro doesn't seem to prevent heart disease and stroke in patients suffering from the irregular heartbeat called atrial fibrillation, a new Canadian study finds.

People with atrial fibrillation are at risk for heart disease and stroke, and lowering blood pressure is one way of staving off these potential problems. Avapro (irbesartan) is an angiotensin-receptor blocker, which lowers blood pressure by helping blood vessels dilate.

"Atrial fibrillation affects between 2 and 6 million men and women in the United States," said Dr. Gregg Fonarow, a spokesman for the American Heart Association and a professor of cardiology at the University of California, Los Angeles.

"Individuals with atrial fibrillation have substantially increased risk for stroke, other cardiovascular events, hospitalizations, and health-care expenditures," he added.

It has been "widely speculated" that angiotensin-receptor blockers might reduce the likelihood of recurrent atrial fibrillation and reduce the risk of cardiovascular events, Fonarow explained.

Earlier studies have suggested that angiotensin-receptor blockers benefit patients with atrial fibrillation, he added.

The latest report is published in the March 10 issue of the New England Journal of Medicine.

For the study, Dr. Salim Yusuf, from McMaster University in Hamilton, and colleagues randomly assigned 9,016 patients with atrial fibrillation to daily doses of Avapro or a placebo. Over about four years of follow-up, the researchers looked for incidents of stroke, heart attack, death and heart failure.

The researchers found that even though people taking Avapro had lower blood pressure than those taking placebo, people in both groups suffered a stroke, heart attack or died at the same rate over the four years.

In addition, those taking Avapro or placebo suffered heart failure at about the same rate, but those taking Avapro had a lower rate of hospitalization for heart failure, the researchers said. Also, there was no benefit from the drug among patients with a normal heart rhythm at the start of the study when it came to preventing hospitalization for atrial fibrillation.

The researchers also found more patients taking Avapro had blood pressure that was too low and more had kidney failure than did those receiving a placebo.

"This study demonstrates Avapro, despite a modest reduction in blood pressure, does not prevent recurrent episodes of atrial fibrillation or prevent cardiovascular events overall," Fonarow said. "There were no differences in heart attacks, cardiovascular deaths or deaths from any cause. There were modestly lower rates of hospitalization for heart failure and any cardiovascular hospitalization."

When this new trial is considered together with an earlier trial, it's evident that this class of blood pressure drugs has no effect in preventing episodes of atrial fibrillation in patients with intermittent atrial fibrillation, he added.

"In the absence of other indications, routine use of angiotensin-receptor blockers in patients with atrial fibrillation does not appear to be warranted," Fonarow said.

More information

For more on atrial fibrillation, visit the American Heart Association.

SOURCES: Gregg Fonarow, M.D., spokesman, American Heart Association, and professor, cardiology, University of California, Los Angeles; March 10, 2011, New England Journal of Medicine


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Redefining normal blood pressure
2. University of South Florida researchers find blood-brain barrier damaged by disease
3. Transplanting umbilical cord and menstrual blood-derived stem cells offer hope for disorders
4. OHSU physician explores method to reduce blood-clot risk in trauma patients
5. University of Nevada, Reno, teams with IMMY to make new life-saving blood test
6. Tight Blood Sugar Control May Put Some Diabetics at Risk
7. Napping May Help Keep Blood Pressure in Check
8. Blood Pressure Drugs May Help Heart Patients Without Hypertension
9. Dramatic Drop in Blood Infections Among ICU Patients: CDC
10. A small subset of normal white blood cells gives rise to a rare leukemia, study shows
11. Simple blood test at discharge could help reduce hospital readmissions for heart failure patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Pressure Drug Does Not Help Those With Atrial Fibrillation 
(Date:8/22/2017)... ... August 22, 2017 , ... The Women’s Choice Award, a growing platform ... with the 2017 Women’s Choice Award. The identification by women of an effective ... 4 migraine sufferers are women. In a survey taken by the Women’s Choice Award ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Each of the past six years, Lightning Labels ... pictures of these labels and stickers, demonstrating the variety and creativity of their designs. Submissions ... label images came in. Now, it's time to announce the winners of the sixth annual ...
(Date:8/22/2017)... ... August 22, 2017 , ... “To Walk Away”: ... a B17 bomber named Edward Koontz. “To Walk Away” is the creation of published ... has published over two hundred manuscripts in chemistry and religion, as well as four ...
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “Glimpses Of ... understanding of the world. “Glimpses Of Light” is the creation of published author, J.M. ... life in search of answers to life’s perplexing mysteries. , Shepherd shares, “Love is ...
(Date:8/22/2017)... , ... August 22, 2017 , ... Although Labor Day ... July, many communities have begun providing weekend displays, and numerous households celebrate the unofficial ... they can be downright terrifying for pets. , Kris Zambo, owner of ...
Breaking Medicine News(10 mins):
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy , will ... Cell-Ess® Universal Titer Boost at the 9 th annual ... 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to ... ... Cell-Ess is the ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., ... , today announced that the company has provided ... University of North Carolina at Chapel Hill and to ... designed to characterize and quantify HIV reservoir and viral ... pharmacological intervention. The HIV Cure Center is a joint ...
Breaking Medicine Technology: